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Abstract 
Bladder cancer is the fifth most common in incidence and one of the most expensive cancers to 
treat. Early detection greatly improves the chances of survival and bladder preservation. The pH 
Low Insertion Peptide (pHLIP® peptide) conjugated with a near infrared fluorescent dye (ICG) 
targets low extracellular pH allowing visualization of malignant lesions in human bladder 
carcinoma ex vivo. Cystectomy specimens obtained after radical surgery were immediately 
irrigated with non-buffered saline and instilled with a solution of the ICG pHLIP® construct, 
incubated, and rinsed. Bladders were subsequently opened and imaged, the fluorescent spots 
were marked, and a standard pathological analysis was carried out to establish the correlation 
between ICG pHLIP® imaging and white light pathological assessment. Accurate targeting of 
bladder lesions was achieved with a sensitivity of 97%. Specificity is 100%, but reduced to 80%, 
if targeting of necrotic tissue from previous transurethral resections or chemotherapy are 
considered as false positives. ICG pHLIP® imaging agent marked high grade urothelial 
carcinomas, both muscle invasive and non-muscle invasive. Carcinoma in situ (CIS) was 
accurately diagnosed in 11 cases, whereas only 4 cases were seen using white light, so imaging 
with the ICG pHLIP® peptide offers improved early diagnosis of bladder cancers, and may also 
enable new treatment alternatives.  
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Significance Statement 
Bladder cancer is the fifth most common cancer. Timely diagnosis and appropriate early 
management protocols are of paramount significance for improving patient outcomes. This is 
the first study to show efficient pH dependent near infrared imaging of bladder malignant 
tumors without targeting of normal tissue. Our results demonstrate that the ICG pHLIP® 
construct is suitable for use as a predictive clinical marker, specifically staining human bladder 
tumors after intravesical administration ex vivo. The targeting allows delivery of various imaging 
probes, which may offer early diagnosis and improve the outcomes of endoscopic and radical 
surgical resection of urothelial carcinomas. In addition; delivery of therapeutic molecules to 
cancer cells by pHLIP® might open an opportunity for novel targeted treatment of bladder 
cancers.    
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Introduction 
Bladder cancer is the fifth most common cancer, constituting 4.5% of all new cancer cases in 
the USA. 76,960 new cases were estimated in 2016 and the death rate currently expected from 
bladder cancer is 21% (16,390). Approximately 2.4 percent of men and women will be 
diagnosed with bladder cancer at some point during their lifetime. In 2012, there were an 
estimated 577,403 individuals living with bladder cancer in the United States. Almost all of 
these patients require continuous surveillance, and, occasionally, treatments. For all stages 
combined, the 5-year relative survival rate is 77%. Survival declines to 70% at 10 years and 65% 
at 15 years after diagnosis. Bladder cancer can be non-muscle or muscle invasive. Half of all 
bladder cancer patients are diagnosed while the tumor is non-muscle invasive, for which the 5-
year survival is 96%. Most (up to 98%) of malignant bladder tumors arise in the epithelium, 90-
92% of these bladder cancers are urothelial carcinomas (1, 2). Less common bladder cancers 
are squamous cell or adenocarcinomas. Approximately 20-25% of patients have muscle invasive 
disease, and of non-muscle invasive disease patients will progress to muscle invasive disease at 
5 years follow up depending on intermediate or high risk of the progression (3, 4). An important 
medical objective is the identification of early stage lesions, such as carcinoma in situ, since it is 
expected that diagnosis at this stage will decrease the frequency of treatments, increasing 
patient health and reducing expense. 
 
Each type and stage of bladder cancer requires a different type of treatment. High recurrence 
frequency, procedural costs, and the requirement for prolonged active monitoring, make 
bladder cancer one of the most expensive cancers in the US, placing a heavy economic burden 
on the healthcare system from lifetime endoscopic follow ups and treatments.  Patients suffer 
from high morbidity and the complications associated with chemotherapy, radiation and radical 
surgery (5). Therefore, as noted, timely diagnosis of the tumor and appropriate management 
protocols are of great significance for decreasing treatment cost and improving a patient’s life 
style. Advances in the early detection of bladder cancer lesions are likely to increase the 
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chances of timely successful treatment, the prevention of recurrences, and bladder function 
preservation.  
  
Cancers, including urothelial carcinoma, are associated with multiple alterations in the genome, 
including changes in epigenetic regulation, point mutations, gene deletions, duplications and 
chromosomal rearrangements. These changes are heterogeneous, leading to heterogeneity of 
the overexpression of particular biomarkers at the surfaces of cancer cells within a tumor and 
between tumors. Heterogeneity significantly limits success in the use of cell surface biomarkers 
for the targeted delivery of therapeutics. On other hand, multiple studies have revealed that 
neoplastic cells produce an acidic environment due to increased metabolic activity (6). 
Adaptations to the highly acidic microenvironment are critical steps in the transition from an 
avascular pre-invasive tumor to a malignant invasive carcinoma (7-9).  Thus, acidity may provide 
a universal biomarker for tumor targeting that is not subject to the selection of resistant cell 
lines (10). pH Low Insertion Peptides (pHLIP® peptides) are a class of membrane-binding 
peptides that specifically target acidic cells in vitro and in vivo (11) by inserting across cellular 
membranes when the extracellular pH is low (12). pHLIP® peptides conjugated with fluorescent 
dyes have been used to differentiate normal from neoplastic tissue in various animal tumor 
models (12-15), and in human biopsy head and neck samples (16, 17). This report is the first 
study using an ICG pHLIP® conjugate for the diagnosis of urothelial carcinoma and precancerous 
lesions in fresh human radical cystectomy samples ex vivo, and points the way toward a wide 
range of diagnostic and therapeutic alternatives. 
 
Results 
We used a pHLIP® peptide labeled with a near-infrared fluorescence (NIRF) dye, ICG, to monitor 
the targeting of tumors in human bladders. The absorption spectrum of ICG pHLIP® is shown in 
Figure 1a. The fluorescence of ICG pHLIP increases about 25 fold in the presence of 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) liposomes (Figure 1b). Thus, binding of 
ICG pHLIP® to the lipid bilayers of cancerous cell membranes significantly enhances the 
emission of ICG.   
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From November 2014 through December 2015, twenty two radical cystectomy patients were 
included in the study.  Patient ages ranged from 51 to 84 (mean age 67.7 years), and the  
gender ratio: M/F was 19/3. Table 1 contains patient demographics, preoperative diagnosis, 
clinical stage of the disease and the results of imaging studies.  The specimens did not show any 
adverse morphological findings after incubation with ICG pHLIP®, and there was no evidence of 
damage or degenerative effect in the non-tumoral tissue. The use of ICG pHLIP® did not alter 
the pathological assessment of the radical cystectomy tissues. Overall, 29 malignant lesions 
were identified by pathology assessment of the 22 bladder specimens stained with ICG pHLIP®  
(3 radical cystectomy cases were incubated ex vivo with ICG-Cys as negative controls). The 
frequencies of different pathologies in 29 lesions were as follows (Figure 2): high grade muscle 
invasive urothelial carcinoma (HGI) in 12; high grade non-muscle invasive urothelial carcinoma 
(HGN) in 5; carcinoma in situ (CIS) in 11, and high grade dysplasia in 1. In 7 cases NIRF imaging 
guided the pathologist to CIS not observed by white light inspection. In case #2 necrotic tissue 
inside a diverticulum was NIRF positive. For the negative control cases (cases #13, 19 and 20) 
only the ICG-Cys dye alone was used for instillation (at concentrations from 8 to 40 M in an 80 
ml volume), and no specific tumor targeting was observed.  
 
The tabular results of the sensitivity/specificity tests are shown in Tables 2-3. The test was 
performed for cancerous versus normal tissue excluding targeting of necrotic and previously 
treated tissue (Tables 2a and 2b). The sensitivity and specificity of targeting of cancerous tissue 
versus normal were found to be 97% and 100%, respectively. If targeting of necrotic tissue from 
prior post trans-urethral removal of bladder tumors and previously treated (chemotherapy) 
necrotic tumors by ICG pHLIP® is considered as a false positive, the specificity is reduced from 
100% to 80% (Tables 3a and 3b).  
 
Discussion 
We used an ICG pHLIP construct to target urothelial carcinoma in human bladder specimens 
immediately after surgical removal. ICG is an FDA approved NIRF dye that does not show any 
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independent propensity for targeting neoplastic tissue as seen in renal cell carcinoma, mostly 
by perfusion and diffusion differences or neoplastic and normal tissue (washout). ICG is in 
clinical use to visualize vasculature or lymphatics (18-20). ICG has a low level of fluorescence in 
aqueous solution, while its emission increases upon binding to hydrophobic pockets of proteins 
(such as albumin) or cellular membranes. Targeting by the pHLIP® peptide is based on low pH-
triggered insertion into the lipid bilayers of cancer cell membranes. Thus, the pHLIP peptide 
tethers the ICG to the membrane, enhancing ICG fluorescence by about 25 fold.  
 
To avoid/minimize targeting of normal cells by the ICG pHLIP peptide, the construct was 
instilled in pH 7.4 PBS supplemented with 10 mM of D-glucose. to promote the uptake of the 
ICG pHLIP peptide by cancer cells. Glycolytic cancer cells exhibit high glucose uptake, which 
enhances acidification of the extracellular space in vitro and in vivo (21). Thus, our goal was to 
selectively promote increased acidity at cancer cell surfaces to enhance pHLIP® peptide 
insertion and targeting, while not affecting normal cells with normal metabolism.  
 
In our study we had a mixture of different subtypes of urothelial carcinoma, as expected given 
that the disease had advanced to the point where the bladder had to be removed. Our cases 
included typical high grade urothelial carcinoma but also had different variants with prominent 
squamous cell differentiation, micropapillary urothelial carcinoma, adenocarcinoma and 
plasmacytoid morphology. It appears that the sensitivity (97%) and specificity (100%) of tumor 
targeting by ICG pHLIP peptide is irrelevant to the subtype of tumor. Half of the cystectomy 
specimens in our study revealed evidence of necrosis and effects from prior treatments, and all 
revealed evidence of residual tumor (invasive or in-situ) adjacent and associated with necrosis, 
which was targeted by  ICG pHLIP peptide, possibly from entrapment or uptake of ICG by 
necrotic areas. Our previous studies did not show targeting of necrotic tissue by pHLIP 
peptides in animal tumor models (14).  If targeting of necrotic and previously treated tissues are 
considered as false positives, the specificity is decreased to 80%, but no false positives were 
seen for unperturbed lesions.  
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One lesion gave a positive NIRF imaging signal in the presence of dysplasia, revealed by 
subsequent pathology analysis. Urothelial dysplasia is an incidental microscopic finding where 
urothelial cells show mild atypical features short of the diagnosis of carcinoma in situ. It is 
considered a pre-cancerous process and studies have shown that up to 19% of urothelial 
dysplasia cases develop urothelial carcinoma (22-24). Although precancerous, it is 
recommended that patients with dysplasia receive proper clinical follow up for early detection 
of an imminent carcinoma. Dysplasia has not been clinically detectable,  so the ICG pHLIP 
peptide may be a useful marker for detection of high grade dysplasia in urothelium, allowing 
early detection of precancerous lesions. 
 
Bladder tissues are prone to inflammation and infection. Long standing inflammation and 
severe infections can cause transformations in the mucosa like cystitis cystica and cystitis 
glandularis that, due to high frequency, are considered normal findings in the urothelium. In 
one case, an area with marked uptake of ICG pHLIP peptide showed cystitis cystica et 
glandularis with chronic inflammation without any evidence of dysplasia or malignancy. It is 
noteworthy that almost all 22 cystectomy specimens revealed some degree of cystitis cystica et 
glandularis somewhere in the specimen. Only two lesions revealed cystitis cystica without any 
other pathology: one lesion (case #9) showed positive signal with ICG pHLIP peptide. When 
the instilled concentration of ICG pHLIP® peptide was reduced to 4 µM, the cystitis cystica in 
the second case (case #18) was not stained. Reducing the concentration of ICG pHLIP peptide 
did not affect targeting of high grade invasive carcinoma and CIS (case #17). We expect that 
optimizing the concentration and shortening the time of the ICG pHLIP® instillation will allow a 
clear signal differentiation among inflamed, necrotic and cancerous tissue. 
 
In summary, the ICG pHLIP peptide is a promising tool for the early detection of urothelial 
carcinoma, regardless of subtype, with high sensitivity and specificity. The detection might be 
used for monitoring the state of disease and/or for marking lesions for surgical removal.  Before 
ICG pHLIP imaging agent enters clinical trial the toxicology and pharmacology studies will be 
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carried out to establish safety profile. The ICG pHLIP imaging agent is expected to improve 
diagnosis and resection of cancerous lesions in the bladder. As a result, the recurrence rate 
might be reduced, patient outcomes could be improved and the cost of medical care for 
bladder cancer will be lowered. In addition, success with targeted imaging could lead to pHLIP® 
delivery of therapeutic molecules to bladder tumor cells, creating an opportunity for targeted 
treatment of bladder cancers.  Currently, we are testing novel pHLIP based therapeutic agents, 
which demonstrate very promising results. Further, the ICG pHLIP construct is a generally 
applicable imaging agent, since it targets a general property of the tumor microenvironment, 
tumor acidity. Once approved for clinical use, it could be tested and possibly used on a variety 
of cancers. We have shown targeting of primary tumors and metastatic lesions by fluorescent 
pHLIP® peptides in more than 15 varieties of human, murine and rat tumors, including 
lymphoma, melanoma, pancreatic, breast and prostate transgenic mouse models and human 
tissue (bladder, kidney, breast and head/neck stained ex vivo). 
 
 
Materials and Methods  
Conjugation of ICG with the pHLIP peptide 
pHLIP variant 3 (Var3) peptide with a single Cys residue at the N-terminus, 
ACDDQNPWRAYLDLLFPTDTLLLDLLWA, was synthesized and purified by reversed phase 
chromatography by CS Bio, Inc. The near infrared fluorescent dye, indocyanine green (ICG) 
maleimide (Intrace Medical), was conjugated to the pHLIP peptide at a ratio of 1:1 in DMF 
(dimethylformamide). The reaction progress was monitored by the reversed phase (Zorbax SB-
C18 columns, 9.4 × 250 mm 5 μm, Agilent Technology) high-performance liquid 
chromatography (HPLC) using a gradient from 5-70% acetonitrile in water containing 0.05% 
trifluoroacetic acid. Also, for the negative control, ICG-malemide was conjugated with the free 
amino aicd, L-cysteine (Sigma).  The concentration of labeled peptide in buffer was determined 
by ICG absorption at 800 nm, ε800=137,000 M
-1 cm−1. The purity of the constructs was 
performed by analytical HPLC and SELDI-TOF mass spectrometry, the amount of free dye in the 
solution was less than 1%. 
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Liposome Preparation  
Large unilamellar vesicles were prepared by extrusion. 2.5 mg POPC (1-palmitoyl-2-oleoyl-
snglycero-3-phosphocholine, Avanti Polar Lipids, Inc.) lipids were dissolved in 0.5 ml 
chloroform, desolvated on a rotary evaporator and dried under high vacuum for 3 hours. The 
phospholipid film was then rehydrated in pH 7.4 PBS containing 10 mM D-glucose, vortexed for 
5 minutes, and repeatedly extruded at least 15 times through a membrane with a 100 nm pore 
size.  
 
Absorption and Fluorescence Measurements  
Absorbance and fluorescence measurements were carried out on a Genesys 10S UV-Vis 
spectrophotometer (Thermo Scientific) and a SpectraMax M2 spectrofluorometer (Molecular 
Devices), respectively. The absorption spectra were measured in PBS pH 7.4 containing 10 mM 
D-glucose from 600 to 850 nm.  The fluorescence spectra of 10 M of ICG pHLIP® peptide were 
measured from 810 to 850 nm at 790 nm excitation wavelength in PBS pH 7.4 containing 10 
mM D-glucose, with or without 2 mM of POPC liposomes. 
 
Ex vivo Imaging of Bladder Specimens 
After obtaining institutional review board (IRB) approval, 22 urothelial carcinoma patients that 
were scheduled for radical cystectomy were selected over a twelve month period and 
appropriate informed consent was obtained. After radical cystectomy, bladder specimens were 
immediately removed and irrigated 3 times for 5 min via catheter with non-buffered saline and 
instilled and incubated with 80 ml of 8 M or 32.8 g/ml (unless otherwise is stated, see notes 
to Table 1) of ICG pHLIP® construct or ICG-Cys in PBS pH 7.4 containing 10 mM D-glucose for 60 
minutes. Then, the unbound constructs were removed by rinsing with 80 ml of saline solution 
3-5 times, the bladder was irrigated thoroughly with buffered saline and opened using a Y 
incision on the anterior wall.  Using a da Vinci Si NIRF imaging system (FireflyR), ex vivo 
fluorescent and white light imaging of the entire bladder and its parts was performed. The 
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fluorescent spots were marked and standard pathological analysis was carried out to explore 
the correlation between appearance of fluorescent signal and cancer lesions.  
 
Pathological Analysis 
The specimen was sectioned and submitted after 24 hour fixation in 10% phosphate-buffered 
formalin according to the standard institutional grossing manual, with emphasis on the marked 
areas of the bladder. The sections were processed for routine histology into paraffin-embedded 
blocks. Five micrometer thick tissue sections were obtained and stained for hematoxylin and 
eosin (H&E). Evaluation of pathology was performed by a genitourinary (GU) pathologist, and a 
standard report was prepared based on the American Joint Committee on Cancer (AJCC) Cancer 
Staging Manual, 7th edition, 2010.  
 
Statistical Analysis 
Statistical parameters were calculated according to the following equations: 
𝑇𝑅𝑃 =
𝑇𝑃
𝑇𝑃+𝐹𝑁
;    𝑆𝑃𝐶 =
𝑇𝑁
𝑇𝑁+𝐹𝑃
 
 𝑃𝑃𝑉 =
𝑇𝑃
𝑇𝑃+𝐹𝑃
;    𝑁𝑃𝑉 =
𝑇𝑁
𝐹𝑁+𝑇𝑁
;  
𝐹𝑃𝑅 =
𝐹𝑃
𝐹𝑃+𝑇𝑁
;    𝐹𝑁𝑅 =
𝐹𝑁
𝑇𝑃+𝐹𝑁
; 
𝐹𝐷𝑅 =
𝐹𝑃
𝑇𝑃+𝐹𝑃
;    𝐹𝑂𝑅 =
𝐹𝑁
𝐹𝑃+𝑇𝑁
 
Where TP is the true positive; TN is the true negative; FP is the false positive; FN is the false 
negative; TRP is the true positive rate or sensitivity; SPC is the true negative rate or specificity; 
PPV is the positive predictive value or precision; NPV is the negative predictive values; FPR is 
the false positive rate; FNR is the false negative rate; FDR is the false discovery rate; FOR is the 
false omission rate.  
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Table 1. Demographic information, pathological stage and diagnosis, lesions seen by white light 
and fluorescence imaging. 
* 40 µM of 80 mL of the construct was used for instillation 
** 4 µM of 80 mL of the construct was used for instillation 
  
Case 
# 
Sex 
Age 
Pathological 
stage 
Pathological diagnosis  Grade Lesion 
number 
White light 
diagnosis 
Fluor. 
1 M/63 pT3aN1 
Infiltrating high grade urothelial carcinoma, CIS & 
necrosis 
HGI 1 + + 
2 M/61 pT0N0 
Diverticulum with urothelial atypia & treatment 
effects 
- - + + 
3
 
F/84 ypT3bN0 
Invasive high grade urothelial carcinoma 
Invasive high grade urothelial carcinoma & necrosis
 
HGI 
HGI 
2 
3 
+ 
+ 
+ 
+ 
4 M/51 pT2aN1 
Residual infiltrative high grade urothelial carcinoma  
micropapillary features, dysplasia & necrosis 
HGI 4 + + 
5 M/69 pTaN0 Non-invasive high grade papillary carcinoma HGN 5 + + 
 
6 
 
M/65 
 
pT1N0 
Residual invasive high grade urothelial carcinoma, CIS 
& necrosis 
CIS 
CIS 
HGI 
 
CIS 
CIS 
6 
 
7 
8 
+ 
 
+ 
+ 
+ 
 
+ 
+ 
7 M/61 pT1N0 
Focally invasive high grade urothelial carcinoma, 
necrosis 
HGI 9 + + 
8 M/79 pT1N0 
Dysplasia 
Treatment effect & CCCG 
DIS 
- 
10 
- 
- 
- 
+ 
+ 
9 M/74 pT0N0 CCCG - - - + 
 
10 
 
F/82 
 
pT1N0 
Non-invasive high grade urothelial carcinoma
 
Invasive high grade urothelial carcinoma 
CIS 
CIS & CCCG 
HGN 
HGI 
CIS 
CIS 
11 
12 
13 
14 
+ 
+ 
- 
- 
+ 
- 
+ 
+ 
11 M/68 pTisN0 
CIS & CCCG 
CIS 
CIS 
CIS 
15 
16 
+ 
- 
+ 
+ 
 
12 
 
M/71 
 
pTisN0 
 
Non-invasive high grade urothelial carcinoma 
Non-invasive high grade urothelial carcinoma 
CIS 
CIS 
HGN 
HGN 
CIS 
CIS 
17 
18 
19 
20 
+ 
+ 
- 
- 
+ 
+ 
+ 
+ 
13* M/66 pT3N1 
Invasive high grade urothelial carcinoma 
Ulceration, necrosis, CCCG
 
  + 
+ 
ICG-Cys 
14 M/66 pT1N0 Non-invasive high grade urothelial carcinoma HGN 21 + + 
15 M/57 pT1N0 Invasive high grade urothelial carcinoma
 
HGI 22 + + 
16 F/77 pTisN0 
CIS with early invasion 
CIS with early invasion 
CIS 
CIS 
23 
24 
+ 
- 
+ 
+ 
17** M/57 pT1bN0 
 
Invasive high grade urothelial carcinoma 
CIS with early invasion 
Necrosis & treatment effect 
HGI 
CIS 
- 
25 
26 
- 
+ 
+ 
+ 
+ 
+ 
+ 
18** M/72 pT3aN0 
Invasive high grade urothelial carcinoma, CIS 
Necrosis & treatment effect in diverticulum 
HGI 
- 
27 
- 
+ 
+ 
+ 
- 
19 M/64 pT2aN0 
Invasive high grade urothelial carcinoma, CIS, Necrosis 
& treatment effect 
  
+ ICG-Cys 
20 M/63 ypT0N0 CCCG and reactive changes in scar   + ICG-Cys 
21 M/74 pT3aN0 
Invasive high grade urothelial carcinoma in scar 
Necrosis  
HGI 
- 
28 
- 
+ 
+ 
+ 
+ 
22** M/66 ypT3aN0 
Invasive high grade urothelial carcinoma with 
neuroendocrine features 
HGI 29 + + 
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Table 2a. Tabular results of the sensitivity/specificity test of ICG pHLIP peptide targeting of 
cancerous lesions in the human bladder specimens: Carcinoma versus Normal excluding 
necrotic tissue and treatment effects. 
Receiver operator characteristics 
carcinoma vs normal 
 
TP + FN 
 
FP + TN 
 
Sum 
TP + FP 
FN + TN 
Sum 
TP, 28 
FN, 1 
29 
FP, 0 
TN, 19 
19 
28 
20 
 
TP is the true positive; TN is the true negative; FP is the false positive; FN is the false negative 
 
 
Table 2b. Descriptive parameters 
Measure Results 
Sensitivity, TRP 
Specificity, SPC 
Positive predictive value, PPV 
Negative predictive values, NPV 
False positive rate, FPR 
False negative rate, FNR 
False discovery rate, FDR 
False omission rate, FOR 
0.966 
1.000 
1.000 
0.950 
0.000 
0.034 
0.000 
0.053 
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Table 3a. Tabular results of the sensitivity/specificity test of ICG pHLIP peptide targeting of 
cancerous lesions in the human bladder specimens: Carcinoma versus Normal including 
necrotic tissue and treatment effects. 
Receiver operator characteristics 
carcinoma vs normal + necrosis 
 
TP + FN 
 
FP + TN 
 
Sum 
TP + FP 
FN + TN 
Sum 
TP, 28 
FN, 1 
29 
FP, 5 
TN, 20 
25 
33 
21 
 
TP is the true positive; TN is the true negative; FP is the false positive; FN is the false negative 
 
 
Table 3b. Descriptive parameters 
Measure Results 
Sensitivity, TRP 
Specificity, SPC 
Positive predictive value, PPV 
Negative predictive values, NPV 
False positive rate, FPR 
False negative rate, FNR 
False discovery rate, FDR 
False omission rate, FOR 
0.966 
0.800 
0.848 
0.952 
0.020 
0.034 
0.152 
0.040 
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Figures Legends 
 
Figure 1. Normalized absorbance (a) and fluorescence (b) spectra are shown of ICG pHLIP® 
construct measured in PBS pH 7.4 containing 10 mM D-glucose. The fluorescence (with an 
excitation wavelength of 790 nm) of ICG pHLIP® construct is increased about 25 fold in the 
presence of POPC liposomes compared to the emission in buffer. 
 
Figure 2. Representative white light (a, d, g, j), NIR fluorescence (b, e, h, k) ex vivo imaging of 
bladder specimens and hemolysin and eosin (HE) stained tumor sections (c, f, i, l)  are shown, 
demonstrating targeting of invasive high grade urothelial carcinoma (a, b, c), non-invasive high 
grade urothelial carcinoma (d, e, f), carcinoma in situ (g, h, i) and dysplasia (j, k, l) by ICG pHLIP® 
imaging agent. The diagnosis was confirmed by pathological analysis. The fluorescent lesions 
were marked in case #11 to identify locations for pathology analysis. 
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Figure 1 
  
 20 
 
Figure 2 
